By Medical Science Correspondent
The traditional approach to managing obesity has long operated under a "one-size-fits-all" framework, treating the condition primarily as an imbalance of caloric intake and energy expenditure. However, groundbreaking research presented at this year’s European Congress on Obesity (ECO) in Istanbul (May 12-15) suggests that this generalized view may be overlooking critical biological nuances. New findings from Dokuz Eylul University indicate that obesity does not manifest identically in men and women, with distinct patterns of fat distribution, metabolic markers, and inflammatory responses emerging between the sexes. These insights could represent a paradigm shift in how clinicians approach personalized obesity treatment.
The Core Findings: A Tale of Two Pathologies
The research team, led by Dr. Zeynep Pekel, undertook a comprehensive analysis of over 1,100 patients to identify how the body’s internal landscape shifts under the weight of obesity. Their data suggests a divergence in health risks: while men appear more prone to the metabolic consequences of visceral fat accumulation, women exhibit a heightened systemic inflammatory profile.
The Male Experience: Visceral Fat and Metabolic Strain
The study found that men living with obesity are significantly more likely to develop "visceral" or abdominal fat—the type that wraps around internal organs like the liver and pancreas. This fat is not merely stored energy; it is metabolically active tissue that secretes hormones and inflammatory proteins directly into the portal circulation, wreaking havoc on the liver. The male participants in the study displayed higher levels of liver enzymes (ALT and GGT), which often serve as a red flag for fatty liver disease and potential organ damage.
The Female Experience: Systemic Inflammation and Lipid Profiles
Conversely, the women in the study presented a different set of challenges. They were more likely to show elevated levels of total cholesterol and "bad" LDL cholesterol. Perhaps more notably, their bodies showed a more pronounced inflammatory response. Markers such as C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and platelet counts were significantly higher in women than in their male counterparts. This chronic, low-grade inflammation is a known precursor to cardiovascular disease and type 2 diabetes, suggesting that for women, the primary battleground in obesity may be the immune system’s reaction to systemic metabolic stress.
Chronology of the Research
The path to these findings began with a recognition of the limitations in existing obesity research. Despite the global prevalence of metabolic syndrome—which currently affects approximately 1.54 billion adults worldwide—most clinical guidelines have failed to account for the biological disparities between the sexes.
- 2023: Global health data highlights that metabolic syndrome, a cluster of conditions including abdominal obesity, hypertension, and high blood glucose, affects 1 in 3 women and 1 in 4 men, emphasizing the urgency of the crisis.
- 2024–2025: Researchers at the Obesity Clinic in the Department of Internal Medicine at Dokuz Eylul University began their observational study. They recruited 886 women (average age 45) and 248 men (average age 41).
- May 2025: The research team compiled their findings, categorizing patient data by BMI, waist circumference, blood pressure, lipid panels, liver/kidney function markers, and inflammatory indicators.
- May 12-15, 2025: The findings were officially presented at the European Congress on Obesity in Istanbul, drawing significant attention from the international medical community.
Supporting Data: By the Numbers
To quantify these differences, the study employed a rigorous diagnostic protocol. The data revealed a stark contrast in physical and chemical markers:
| Metric | Men (Avg) | Women (Avg) |
|---|---|---|
| BMI | 37.5 kg/m² | 36.0 kg/m² |
| Waist Circumference | 120 cm | 108 cm |
| Systolic Blood Pressure | 128 mmHg | 122 mmHg |
| Total Cholesterol | 203 mg/dL | 215 mg/dL |
| LDL Cholesterol | 123 mg/dL | 130 mg/dL |
The data confirms that while men may have a slightly higher average BMI and larger waist circumferences, women exhibit higher concentrations of cardiovascular-risk-associated cholesterol. Furthermore, the elevated creatinine levels in men corroborated the findings of higher metabolic stress, while the higher inflammatory markers in women pointed toward a distinct immune-mediated pathway.
Official Responses and Expert Commentary
Dr. Zeynep Pekel, the lead author of the study, emphasized the necessity of moving away from gender-blind medicine. "Our findings reveal intriguing differences in the way men and women respond to obesity," Dr. Pekel stated. "They show just how important gender-specific research is. Not only are sex differences a powerful player in the pathology and course of obesity, but our results indicate that such differences could be a stepping stone toward finding targeted, sex-based therapies."
Pekel further elaborated on the biological underpinnings of these trends. Hormones, particularly estrogen, play a complex role in regulating fat storage and the body’s inflammatory response. Estrogen generally influences fat distribution to be subcutaneous (under the skin), which is considered less metabolically dangerous than the visceral fat more commonly found in men. Furthermore, the genetic architecture of the X chromosome may contribute to the more robust, and sometimes more reactive, immune responses seen in women.
"It’s still early days," Pekel cautioned, "and these findings need to be confirmed in other patient groups, but they offer important insight into how obesity may affect men and women differently. Our next steps are to validate these findings in larger, more diverse populations."
Implications for Future Clinical Practice
The implications of this research are far-reaching. If obesity is a heterogeneous disease that follows different paths based on biological sex, then the standard of care must evolve.
1. Tailored Diagnostic Screening
If men are at higher risk for liver-related metabolic complications, screening protocols for men should perhaps prioritize liver enzyme monitoring and visceral fat imaging. Conversely, if women are more prone to systemic inflammation and lipid imbalances, their clinical focus might benefit from more aggressive monitoring of inflammatory biomarkers and lipid management strategies.
2. Personalized Therapeutic Interventions
The study suggests that sex-based therapies could become a reality. For instance, if a woman’s obesity is driven heavily by an inflammatory response, anti-inflammatory dietary or pharmaceutical interventions might be more effective than those primarily focused on simple weight reduction. For men, interventions aimed at mobilizing visceral fat might yield faster improvements in liver health and blood pressure.
3. Addressing Health Disparities
By recognizing that 1 in 3 women and 1 in 4 men are currently dealing with metabolic syndrome, healthcare providers can use these findings to better communicate risks to their patients. Understanding that "obesity" is not a single diagnosis but a spectrum of conditions influenced by biology can reduce the stigma associated with the disease and empower patients to engage in more specific, effective health management.
Limitations and Future Outlook
Despite the compelling nature of these results, the researchers are careful to acknowledge the limitations inherent in their methodology. The study was cross-sectional, meaning it provides a "snapshot" of health and cannot definitively prove that obesity causes these specific markers to diverge, or that these markers are not affected by reverse causation.
Additionally, the study cohort was primarily of Turkish ethnicity. Genetics, lifestyle, and dietary habits vary significantly across the globe, meaning these results may not be perfectly applicable to all ethnic or geographical populations. The researchers have called for larger, longitudinal, and multi-ethnic studies to confirm whether these patterns hold true on a global scale.
As the medical community continues to grapple with the global obesity epidemic, the work presented at the ECO serves as a vital reminder: the body’s reaction to excess weight is a sophisticated biological interaction. By acknowledging the distinct roles of hormones, genetics, and fat distribution, medicine can finally begin to offer the personalized, targeted, and effective care that millions of patients worldwide require. Moving forward, the goal is clear: transition from treating the BMI to treating the individual.
